Longboard Pharmaceuticals Inc 's ROA from the third quarter of 2024 to the third quarter of 2023 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Longboard Pharmaceuticals Inc 's ROA in the third quarter of 2024?
Longboard Pharmaceuticals Inc recorded a cumulative net loss of $-76 million during 12 months ending in the third quarter of 2024, resulting in a negative return on assets (ROA) of -30.89%.

However, within the Healthcare sector 472 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2024 quarter, so far to 3942, from total ROA ranking in the second quarter of 2024 at 4022.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Sep 30 2024) III. Quarter	(Jun 30 2024) II. Quarter	(Mar 31 2024) I. Quarter	(Dec 31 2023) IV. Quarter	(Sep 30 2023) III. Quarter
Y / Y Total Assets Change	404.67 %	372.47 %	311.05 %	-28.24 %	-27.01 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-76	-65	-58	-54	-51
Return On Assets (TTM)	-30.89 %	-34.51 %	-46.04 %	-85.18 %	-73.65 %
LBPH's Total Ranking	# 3942	# 4022	# 4286	# 5370	# 4735
Total Assets (TTM) in million	297	313	328	51	59
Seq. Total Assets Change	-5.05 %	-4.47 %	546.37 %	-13.93 %	-11.11 %
Seq. Net Income Change	-	-	-	-	-

LBPH's 5 Years Annual ROA >> Back to LBPH Management Effectiveness >> Compare LBPH ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 188
Sector	# 473
Overall	# 3873

Return On Assets Statistics
High	Average	Low
-23.69 %	-47.96 %	-85.21 %
(Dec 31 2021)		(Dec 31 2023)

Financial Statements
Longboard Pharmaceuticals Inc 's Assets	$ 297 million	LBPH's Balance sheet
Longboard Pharmaceuticals Inc 's Income	$ -25 million	Quarterly LBPH's Income Statement
LBPH's Income by Division		See LBPH's Income by Division

Annual Return On Assets	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021	FY	FY
Y / Y Total Assets Change	-28.24 %	-35.16 %	-	-	-
Total Assets in million	51	71	109	0	0
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-54	-44	-28	0	0
Annual Return On Assets	-107.35 %	-62.2 %	-25.51 %	-	-

LBPH's 5 Years Annual ROA >> Back to LBPH Management Effectiveness >> Compare LBPH ROA to its Competitors

More Return On Assets Ratios
LBPH's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
LBPH's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for LBPH's Competitors
Subscribers only: Roa for Longboard Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Assets for LBPH's Customers

You may also want to know
LBPH's Roi	LBPH's Inventory Turnover Ratio	LBPH's Growth Rates	LBPH's Dividend Comparisons
	LBPH's Profitability Ratios	LBPH's Asset Turnover Ratio	LBPH's Dividend Growth
LBPH's Roe	LBPH's Valuation Ratios	LBPH's Financial Strength Ratios	LBPH's Dividend Payout Ratio

Companies with similar Return On Assets at Sep 30 2024, within Healthcare Sector

ROA

Date modified: 2026-09-08T20:32:22+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.